Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Stock analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for Axsome Therapeutics in a research note issued on Tuesday, March 11th. Zacks Research analyst R. Department anticipates that the company will post earnings per share of $5.75 for the year. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The firm had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million.
AXSM has been the subject of a number of other reports. Needham & Company LLC reiterated a "buy" rating and set a $153.00 price target on shares of Axsome Therapeutics in a research report on Monday, March 3rd. Morgan Stanley raised their price objective on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. Cantor Fitzgerald reissued an "overweight" rating and set a $153.00 price objective on shares of Axsome Therapeutics in a research note on Wednesday, February 19th. Deutsche Bank Aktiengesellschaft began coverage on shares of Axsome Therapeutics in a research note on Tuesday, February 11th. They issued a "buy" rating and a $176.00 target price for the company. Finally, Wells Fargo & Company lifted their target price on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 12th. One equities research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $167.36.
Check Out Our Latest Research Report on AXSM
Axsome Therapeutics Stock Performance
Shares of NASDAQ AXSM traded up $3.77 during midday trading on Thursday, reaching $125.68. 458,938 shares of the company were exchanged, compared to its average volume of 644,274. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. Axsome Therapeutics has a 1 year low of $64.11 and a 1 year high of $139.13. The stock has a fifty day simple moving average of $112.25 and a 200 day simple moving average of $98.96. The stock has a market cap of $6.13 billion, a P/E ratio of -20.98 and a beta of 1.00.
Insider Activity at Axsome Therapeutics
In related news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the transaction, the chief financial officer now owns 42,187 shares in the company, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 22.40% of the company's stock.
Institutional Trading of Axsome Therapeutics
Several large investors have recently modified their holdings of AXSM. Versor Investments LP purchased a new position in Axsome Therapeutics in the third quarter valued at about $791,000. Royce & Associates LP boosted its stake in shares of Axsome Therapeutics by 73.1% during the 3rd quarter. Royce & Associates LP now owns 22,500 shares of the company's stock valued at $2,022,000 after buying an additional 9,500 shares during the last quarter. Whalen Wealth Management Inc. acquired a new stake in shares of Axsome Therapeutics during the third quarter worth approximately $236,000. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of Axsome Therapeutics in the third quarter worth $830,000. Finally, Moors & Cabot Inc. acquired a new stake in Axsome Therapeutics in the third quarter valued at $200,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.
About Axsome Therapeutics
(
Get Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Featured Stories
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
